Health
globalreutersDecember 2, 20241 Mins read
Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited Metabolic Disease
globalreutersDecember 2, 20241 Mins read 
The FDA cited deficiencies in its govorestat’s application in galactosemia, a rare metabolic disease, Applied Therapeutics said. The biotech is still on track to submit a separate application for the drug in sorbitol dehydrogenase (SORD) deficiency, another rare disease that has no FDA-approved therapies.
The post Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited Metabolic Disease appeared first on MedCity News.
Related Articles
The U.S. & The Global Fund to Fight AIDS, Tuberculosis and Malaria
This updated fact sheet examines the U.S. role in the Global Fund,...
Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond
Keros Therapeutics will present Phase 2 data for the drug, elritercept, at...
ভারতে বেনাইন বোন টিউমার অপসারণ চিকিত্সার জন্য সেরা হাসপাতাল
সৌম্য হাড়ের টিউমার একটি উদ্বেগজনক রোগ নির্ণয় হতে পারে, তবে ভালো বিষয়...
Leave a comment